CV Therapeutics: Co-Promoting Without Pharma
Consolidation in the pharmaceutical industry probably means that small biotechs like CVT will find drug companies either uninterested in co-promoting niche products or looking for too large a piece of the profits. Through its innovative deal with Quintiles' CSO, Innovex, CVT obtains considerable sales and marketing muscle, some up-front cash that it can invest in R&D, and gets to keep most of the profits from ranolazine. Innovex, on the other hand, stands to garner royalty payments that will substantially exceed its fee for service margins.There are likely to be more Innovex/CVT-type deals in the near future, as biotechs look for a share in the profits of the drugs that they help to sell. But biotechs like CVT have other options when it comes to co-promotion partners, including Big Biotech, medium-sized drug companies, and ex-US firms looking to increase their US presences.
You may also be interested in...
The drug industry has accepted the need to outsource R&D--now, with sales productivity down, and the rising cost and risk of owning too much commercial infrastructure, why not outsource more of the sales effort, too? Big and small pharmas resist the idea but will eventually have to accept it--junior partners in licensing deals are insisting on roles in selling their own products, and Big Pharma must investigate cost-saving solutions.
The company announced new research investments and partnerships with the American Diabetes Association and the T1D Exchange to address racial disparities in treatment of diabetes.
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.